Increased serum interleukin-6 level as a predictive biomarker for atrial fibrillation: A systematic review and meta-analysis

Wong, 2017, Epidemiology of atrial fibrillation: the Australian and Asia-Pacific perspective, Heart Lung Circ, 26, 870, 10.1016/j.hlc.2017.05.120 Sun, 2009, Predictors of stroke risk in native Chinese with nonrheumatic atrial fibrillation: retrospective investigation of hospitalized patients, Clin Cardiol, 32, 76, 10.1002/clc.20232 Ceornodolea, 2017, Epidemiology and management of atrial fibrillation and stroke: review of data from four European countries, Stroke Res Treatment, 2017, 1, 10.1155/2017/8593207 Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 Jia-Yuan Chen, 2013, CHADS2 versus CHA2DS2-VASc score in assessing the stroke and throm-boembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis, J Geriatr Cardiol, 10, 258 Rivera-Caravaca, 2019, Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores, Stroke, 50, 1372, 10.1161/STROKEAHA.118.024305 Dawood, 2016, High-sensitivity C-reactive protein and risk of stroke in atrial fibrillation (from the reasons for geographic and racial differences in stroke study), Am J Cardiol, 118, 1826, 10.1016/j.amjcard.2016.08.069 Chang, 2017, C-reactive protein gene polymorphism predicts the risk of thromboembolic stroke in patients with atrial fibrillation: a more than 10-year prospective follow-up study, J Thromb Haemost, 15, 1541, 10.1111/jth.13735 Harada, 2015, Role of inflammation in atrial fibrillation pathophysiology and management, Circ J, 79, 495, 10.1253/circj.CJ-15-0138 Lewicka, 2015, Neopterin and interleukin-6 as predictors of recurrent atrial fibrillation, Anat J Cardiol, 16, 563 Hijazi, 2016, Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation, Heart, 102, 508, 10.1136/heartjnl-2015-308887 Hozo, 2005, Estimating the mean and variance from the median, range, and the size of a sample, BMC Med Res Methodol, 5, 13, 10.1186/1471-2288-5-13 Aulin, 2015, Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation, Am Heart J, 170, 1151, 10.1016/j.ahj.2015.09.018 Conway, 2004, Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation, Am Heart J, 148, 462, 10.1016/j.ahj.2004.01.026 Roldán, 2012, High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation, J Thromb Haemost, 10, 1500, 10.1111/j.1538-7836.2012.04812.x Tanaka, 2014, IL-6 in inflammation, immunity, and disease, Cold Spring Harbor Perspect Biol, 6, a016295, 10.1101/cshperspect.a016295 Kumar, 2011, Pathogen recognition by the innate immune system, Int Rev Immunol, 30, 16, 10.3109/08830185.2010.529976 Akira, 1993, Interleukin-6 in biology and medicine, Adv Immunol, 54, 1, 10.1016/S0065-2776(08)60532-5 Heinrich, 1990, Interleukin-6 and the acute phase response, Biochem J, 265, 621, 10.1042/bj2650621 Ishibashi, 1989, Interleukin-6 is a potent thrombopoietic factor in vivo in mice, Blood, 74, 1241, 10.1182/blood.V74.4.1241.1241 Gao, 2017, Human IL-6, IL-17, IL-1beta, and TNF-alpha differently regulate the expression of pro-inflammatory related genes, tissue factor, and swine leukocyte antigen class I in porcine aortic endothelial cells, Xenotransplantation, 24, 1, 10.1111/xen.12291 Gao, 2018, Porcine IL-6, IL-1beta, and TNF-alpha regulate the expression of pro-inflammatory-related genes and tissue factor in human umbilical vein endothelial cells, Xenotransplantation, 25, pe12408, 10.1111/xen.12408 Bittar, 2015, Long-term increased factor VIII levels are associated to interleukin-6 levels but not to post-thrombotic syndrome in patients with deep venous thrombosis, Thromb Res, 135, 497, 10.1016/j.thromres.2014.12.024 Chin, 2003, Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis, Blood Coagul Fibrinol, 14, 515, 10.1097/00001721-200309000-00001 Undar, 1999, Circadian variations in natural coagulation inhibitors protein C, protein S and antithrombin in healthy men: a possible association with interleukin-6, Thromb Haemost, 81, 571, 10.1055/s-0037-1614526 Rochfort, 2015, Thrombomodulin regulation in human brain microvascular endothelial cells in vitro: role of cytokines and shear stress, Microvasc Res, 97, 1, 10.1016/j.mvr.2014.09.003 Willoughby, 2010, Atrial platelet reactivity in patients with atrial fibrillation, Heart Rhythm, 7, 1178, 10.1016/j.hrthm.2010.01.042 Negi, 2015, A circulating biomarker risk-prediction model correlates with CHADS-2 risk score in chronic atrial fibrillation, IJC Metab Endocr, 6, 24, 10.1016/j.ijcme.2015.01.002 Kikuchi, 2019, Comparison of anti-inflammatory effects of rivaroxaban vs. dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study): multicenter randomized study, Heart Vessels, 34, 1002, 10.1007/s00380-018-01324-7